Aktuellt
SENASTE
Redeye sees the CMS draft decision yesterday to not pay for Aduhelm as the latest in a string of rejections of the ill-fated Biogen drug. On the basis of the solid clinical data, we expect lecanemab's approval process and potential rollout to be very different, and Eisai to be much more successful in persuading stakeholders.
LÄS MER
